Drug Trial Radar · NCT05133297
The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Sep 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Feb 16, 2022
Primary completion
Dec 19, 2022
Study completion May 30, 2023
Sponsor
- Lead sponsor
- Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, double-dummy, tofacitinib-parallel-group, phase 2A study to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subject who had an inadequate response or intolerance to methotrexate.
Conditions
- Rheumatoid Arthritis
Interventions
TLL-018Drug
Oral tablets administered at dose1 BID daily for 24 weeks.
TLL-018Drug
Oral tablets administered at dose2 BID daily for 24 weeks.
TLL-018Drug
Oral tablets administered at dose3 BID daily for 24 weeks.
TofacitinibDrug
Oral tablets administered at 5 mg BID daily for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants American College of Rheumatology 50% (ACR50) Response at Week 12Time frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.